RxSight, Inc. (NASDAQ:RXST) Director Tamara Fountain Sells 7,000 Shares of Stock

RxSight, Inc. (NASDAQ:RXST) Director Tamara Fountain sold 7,000 shares of RxSight stock in a transaction on Wednesday, March 12th. The shares were sold at an average price of $25.71, for a total value of $179,970.00. Following the sale, the director now directly owns 24,793 shares of the company’s stock, valued at $637,428.03. This represents a 22.02 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link.

RxSight Stock Down 3.3 %

Shares of RXST stock opened at $25.22 on Friday. The company has a 50 day moving average price of $30.76 and a 200-day moving average price of $41.40. RxSight, Inc. has a 52 week low of $24.64 and a 52 week high of $66.54. The firm has a market capitalization of $1.02 billion, a PE ratio of -30.39 and a beta of 1.22.

RxSight (NASDAQ:RXST) last posted its earnings results on Tuesday, February 25th. The company reported ($0.15) EPS for the quarter, missing analysts’ consensus estimates of $0.10 by ($0.25). The company had revenue of $40.21 million during the quarter, compared to the consensus estimate of $40.23 million. RxSight had a negative return on equity of 14.00% and a negative net margin of 23.92%. Analysts anticipate that RxSight, Inc. will post -0.7 earnings per share for the current year.

Institutional Trading of RxSight

Large investors have recently modified their holdings of the company. Quarry LP boosted its position in RxSight by 82.3% in the third quarter. Quarry LP now owns 638 shares of the company’s stock worth $32,000 after purchasing an additional 288 shares during the last quarter. Point72 Hong Kong Ltd bought a new position in shares of RxSight in the 3rd quarter worth approximately $34,000. Private Trust Co. NA bought a new position in shares of RxSight in the 4th quarter worth approximately $34,000. State of Wyoming purchased a new position in shares of RxSight in the fourth quarter worth approximately $37,000. Finally, Coppell Advisory Solutions LLC grew its position in RxSight by 108.9% during the fourth quarter. Coppell Advisory Solutions LLC now owns 1,289 shares of the company’s stock valued at $44,000 after buying an additional 672 shares during the period. Institutional investors own 78.78% of the company’s stock.

Analyst Ratings Changes

A number of brokerages have commented on RXST. JPMorgan Chase & Co. reduced their price target on shares of RxSight from $62.00 to $40.00 and set an “overweight” rating on the stock in a research report on Wednesday, February 26th. Wells Fargo & Company dropped their price objective on RxSight from $40.00 to $35.00 and set an “equal weight” rating for the company in a report on Wednesday, February 26th. Stifel Nicolaus reduced their price target on shares of RxSight from $35.00 to $33.00 and set a “hold” rating on the stock in a research report on Wednesday, February 26th. UBS Group started coverage on RxSight in a report on Friday, December 6th. They issued a “buy” rating and a $52.00 price objective for the company. Finally, Needham & Company LLC reiterated a “buy” rating and set a $43.00 target price on shares of RxSight in a report on Wednesday, February 26th. Two analysts have rated the stock with a hold rating and six have given a buy rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $51.63.

RxSight Company Profile

RxSight, Inc, a commercial-stage medical device company, engages in the research and development, manufacture, and sale of light adjustable intraocular lenses (LAL) used in cataract surgery in the United States and internationally. It offers RxSight system that enables doctors to customize and enhance the visual acuity for patients after cataract surgery.